Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

PharmaSphere Consulting ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0%   Bankruptcy risk   10.4% 9.6% 11.8% 7.7% 7.8% 8.4% 16.5% 16.5%   Credit score (0-100)   25 25 19 31 30 29 11 11   Credit rating   BB BB BB BB BB BB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   383 294 138 916 1,680 2,630 0.0 0.0   EBITDA   319 35.7 116 345 413 888 0.0 0.0   EBIT   319 35.7 116 345 413 888 0.0 0.0   Pre-tax profit (PTP)   317.8 31.9 112.4 341.8 410.4 883.3 0.0 0.0   Net earnings   248.0 24.8 87.7 266.4 319.6 688.5 0.0 0.0   Pre-tax profit without non-rec. items   318 31.9 112 342 410 883 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   300 75.3 138 317 386 745 95.0 95.0   Interest-bearing liabilities   0.0 4.1 11.2 0.0 75.4 0.0 0.0 0.0   Balance sheet total (assets)   537 128 204 663 1,013 1,378 95.0 95.0   Net Debt   -213 -82.7 -192 -563 -228 -303 -95.0 -95.0     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   383 294 138 916 1,680 2,630 0.0 0.0   Gross profit growth   -53.7% -23.0% -53.2% 564.6% 83.4% 56.5% -100.0% 0.0%   Employees   1 1 1 1 1 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   537 128 204 663 1,013 1,378 95 95   Balance sheet change%   49.7% -76.1% 59.3% 224.3% 52.8% 36.1% -93.1% 0.0%   Added value   319.1 35.7 116.4 345.4 413.3 887.5 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   83.4% 12.1% 84.5% 37.7% 24.6% 33.8% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   71.5% 11.2% 70.0% 79.6% 49.3% 74.4% 0.0% 0.0%   ROI %   159.1% 19.5% 101.9% 148.3% 106.2% 147.4% 0.0% 0.0%   ROE %   123.1% 13.2% 82.2% 117.2% 90.9% 121.7% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   55.9% 58.7% 67.5% 47.8% 38.2% 54.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -66.6% -231.8% -164.8% -163.1% -55.1% -34.1% 0.0% 0.0%   Gearing %   0.0% 5.4% 8.1% 0.0% 19.5% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 252.6% 52.4% 63.8% 7.8% 16.0% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   2.3 2.4 3.1 1.9 1.6 2.2 0.0 0.0   Current Ratio   2.3 2.4 3.1 1.9 1.6 2.2 0.0 0.0   Cash and cash equivalent   212.6 86.8 203.1 563.3 303.3 303.1 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   300.5 75.3 137.9 316.8 386.5 745.0 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   319 36 116 345 413 444 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   319 36 116 345 413 444 0 0   EBIT / employee   319 36 116 345 413 444 0 0   Net earnings / employee   248 25 88 266 320 344 0 0